title: Synthesis and In Vitro Biological Evaluation of 1,3,4-Oxadiazol-2(3H)-one and Tetrahydropyridazine-3,6-dione Derivatives of Fatty Acids.
abstract: Herein we report saturated and unsaturated fatty acid derivatives of 1,3,4-oxadiazol-2(3H)-one and tetrahydropyridazine-3,6-dione as new potential anticancer agents. All the synthesised compounds were characterised by IR, (1)H-NMR, (13)C-NMR, and mass spectral data. The relative sensitivity of three cancer cell lines varied depending on the nature of the compound. Among the most effective anticancer compounds studied, 3b and 6b displayed remarkable anticancer activity against the MDA-MB-231 and KCL-22 lines, respectively. On the other hand, compound 3c was found to be most sensitive to nearly all the tested cell lines, MDA-MB-231, KCL-22, and HeLa.
authors.affiliation: Department of Chemistry, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India.
authors.forename: Mohammad F
authors.initials: MF
authors.lastname: Hassan
authors.affiliation: Department of Chemistry, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India.
authors.forename: Abdul
authors.initials: A
authors.lastname: Rauf
authors.affiliation: Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202 002, India.
authors.forename: Asif
authors.initials: A
authors.lastname: Sherwani
authors.affiliation: Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202 002, India.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Owais
keywords: 1,3,4-Oxadiazol-2-one; Cytotoxicity; Fatty acids; SAR; Tetrahydropyridazine-3,6-dione
references.citation: Bioorg Med Chem. 2006 Feb 15;14(4):1236-46
references.pmid: 16242340
references.citation: Eur J Med Chem. 2005 Feb;40(2):173-84
references.pmid: 15694652
references.citation: Eur J Med Chem. 2012 Mar;49:304-9
references.pmid: 22305543
references.citation: Chem Pharm Bull (Tokyo). 2003 Apr;51(4):427-30
references.pmid: 12672999
references.citation: Eur J Med Chem. 2012 Jan;47(1):473-8
references.pmid: 22119130
references.citation: Bioorg Med Chem. 2008 Apr 1;16(7):3791-9
references.pmid: 18295493
references.citation: J Enzyme Inhib Med Chem. 2010 Apr;25(2):266-71
references.pmid: 20038271
references.citation: Eur J Med Chem. 2013;70:887-900
references.pmid: 24262381
references.citation: Mini Rev Med Chem. 2015;14(13):1093-103
references.pmid: 25429662
references.citation: Eur J Med Chem. 2009 Sep;44(9):3760-4
references.pmid: 19535179
references.citation: Bioorg Med Chem. 2010 Nov 15;18(22):7836-41
references.pmid: 20947362
references.citation: Eur J Med Chem. 2010 Jun;45(6):2283-90
references.pmid: 20189270
references.citation: Nat Rev Drug Discov. 2009 Oct;8(10):806-23
references.pmid: 19794444
references.citation: Eur J Med Chem. 2010 May;45(5):1746-52
references.pmid: 20116141
references.citation: Eur J Med Chem. 2009 May;44(5):1989-96
references.pmid: 19013692
references.citation: Bioorg Med Chem. 2008 Feb 15;16(4):1822-31
references.pmid: 18248993
references.citation: Eur J Med Chem. 2010 Mar;45(3):1206-10
references.pmid: 20004043
references.citation: Bioorg Med Chem. 2014 Feb 1;22(3):1008-15
references.pmid: 24411198
references.citation: J Pharm Sci. 1994 Feb;83(2):246-8
references.pmid: 8169798
references.citation: Farmaco. 2004 Jun;59(6):457-62
references.pmid: 15178308
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Steroids. 2013 Dec 11;78(12-13):1263-72
references.pmid: 24064114
references.citation: Bioorg Med Chem Lett. 2010 Mar 15;20(6):1933-8
references.pmid: 20172722
references.citation: Eur J Med Chem. 2007 Jul;42(7):893-901
references.pmid: 17418454
references.citation: Bioorg Med Chem. 2013 Jan 1;21(1):102-13
references.pmid: 23211969
references.citation: Biol Pharm Bull. 2000 Nov;23(11):1391-4
references.pmid: 11085375
references.citation: Eur J Med Chem. 2009 Jun;44(6):2673-8
references.pmid: 19171410